AgomAb Therapeutics has raised $74 million to advance regenerative pathway modulators in inflammatory, metabolic and fibrotic diseases. The pipeline is led by an HGF-mimetic agonistic antibody developed using argenx’s platform.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,